← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

DBV Technologies S.A. (DBVT) 10-Year Financial Performance & Capital Metrics

DBVT • • Industrial / General
HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune
AboutDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Show more
  • Revenue $0 -100.0%
  • EBITDA -$114M -79.7%
  • Net Income -$114M -56.4%
  • EPS (Diluted) -5.90 -55.3%
  • Gross Margin -
  • EBITDA Margin -
  • Operating Margin -
  • Net Margin -
  • ROE -135.72% -212.3%
  • ROIC -2231.7% -109.1%
  • Debt/Equity 0.28 +509.0%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Momentum leader: RS Rating 91 (top 9%)

✗Weaknesses

  • ✗Weak Piotroski F-Score: 1/9
  • ✗Expensive at 13.2x book value
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-
3Y-
TTM-95.5%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-23%

EPS CAGR

10Y-
5Y-
3Y-
TTM-9.43%

ROCE

10Y Avg-68.09%
5Y Avg-73.16%
3Y Avg-78.06%
Latest-133.79%

Peer Comparison

Dermatology & Autoimmune
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
AUPHAurinia Pharmaceuticals Inc.1.96B14.87378.3733.97%29.28%21.28%2.25%0.21
ARGXargenx SE50.33B813.2463.6378.6%23.34%15.14%0.01
INVAInnoviva, Inc.1.48B19.7654.8915.54%32.78%12.61%12.75%0.65
GLPGGalapagos N.V.2.24B34.0330.3814.99%-151.94%-15.16%0.00
PTGXProtagonist Therapeutics, Inc.5.3B84.7520.046.24%21.94%7.11%3.45%0.02
ALMSAlumis Inc. Common Stock2.84B24.17-2.33-11.08%-63.71%0.12
PHATPhathom Pharmaceuticals, Inc.1.17B14.98-2.8380.01%-186.53%
ORKAOruka Therapeutics, Inc.1.57B32.50-6.51-22.44%0.00

Profit & Loss

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+220.85K7.93M11.52M12.81M14.71M11.28M5.71M4.8M15.73M0
Revenue Growth %-0.14%34.89%0.45%0.11%0.15%-0.23%-0.49%-0.16%2.28%-1%
Cost of Goods Sold+139.94K1.42M3.43M5.03M009.27M20.3M06.81M
COGS % of Revenue0.63%0.18%0.3%0.39%--1.62%4.23%--
Gross Profit+80.9K7.93M11.52M12.81M14.71M11.28M-3.56M-15.5M15.73M-6.81M
Gross Margin %0.37%1%1%1%1%1%-0.62%-3.23%1%-
Gross Profit Growth %-0.11%96.98%0.45%0.11%0.15%-0.23%-1.32%-3.35%2.01%-1.43%
Operating Expenses+54.43M128M185.46M203.22M192.8M170.12M93.93M101.47M92.16M113.71M
OpEx % of Revenue246.44%16.15%16.1%15.86%13.11%15.09%16.46%21.14%5.86%-
Selling, General & Admin18.89M48.49M61.47M82.19M70.73M44.96M23.83M17.56M31.94M23.81M
SG&A % of Revenue85.52%6.12%5.34%6.41%4.81%3.99%4.17%3.66%2.03%-
Research & Development36.85M82.9M126.25M123.5M112.24M101.61M70.34M75.5M60.22M89.9M
R&D % of Revenue166.88%10.46%10.96%9.64%7.63%9.01%12.32%15.73%3.83%-
Other Operating Expenses-6.44M-3.65M-5.21M-6.96M9.83M23.55M-232K8.41M-1K0
Operating Income+-54.34M-122.13M-173.94M-190.12M-171.02M-158.84M-98.61M-96.63M-76.43M-120.53M
Operating Margin %-246.03%-15.41%-15.1%-14.84%-11.63%-14.09%-17.28%-20.13%-4.86%-
Operating Income Growth %-0.82%-1.25%-0.42%-0.09%0.1%0.07%0.38%0.02%0.21%-0.58%
EBITDA+-53.06M-120.63M-170.64M-186.88M-168.43M-148.38M-90.24M-76.33M-63.27M-113.71M
EBITDA Margin %-240.24%-15.22%-14.81%-14.58%-11.45%-13.16%-15.81%-15.9%-4.02%-
EBITDA Growth %-0.83%-1.27%-0.41%-0.1%0.1%0.12%0.39%0.15%0.17%-0.8%
D&A (Non-Cash Add-back)1.28M1.49M3.3M3.24M2.6M10.46M8.38M20.3M13.16M6.81M
EBIT-48.68M-121.74M-173.36M-190.43M-171.02M-135.29M-99.53M-96.98M-76.43M-117.8M
Net Interest Income+953.36K1.58M-3.25M162.44K-1.5M-724K-169K-20.71K3.71M2.73M
Interest Income1.11M1.59M867.09K563.94K75.05K0521K406.29K3.71M2.73M
Interest Expense159.62K17.65K3.99M479.76K1.79M724K690K427K00
Other Income/Expense1.04M1.66M-3.25M161.53K-378K-723K424K427K3.71M2.73M
Pretax Income+-48.52M-126.35M-177.11M-190.24M-171.4M159.56M-98.19M-96.2M-72.72M-117.8M
Pretax Margin %-219.7%-15.94%-15.38%-14.85%-11.65%14.15%-17.2%-20.04%-4.62%-
Income Tax+1.21M1.67M1.2K17.16K610K10K-381K70K7K-4.08M
Effective Tax Rate %1%1%1%1%1%-1%1%1%1%0.97%
Net Income+-48.52M-126.35M-177.2M-190.26M-172.01M-159.56M-97.81M-96.3M-72.73M-113.72M
Net Margin %-219.7%-15.94%-15.38%-14.85%-11.7%-14.15%-17.14%-20.06%-4.62%-
Net Income Growth %-0.67%-1.6%-0.4%-0.07%0.1%0.07%0.39%0.02%0.24%-0.56%
Net Income (Continuing)-49.54M-120.55M-177.2M-190.26M-172.01M-159.56M-98.05M-96.27M-72.73M-113.72M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)+-10.35-4.90-42.00-39.25-26.40-14.75-8.90-6.20-3.80-5.90
EPS Growth %-0.2%0.53%-7.57%0.07%0.33%0.44%0.4%0.3%0.39%-0.55%
EPS (Basic)-10.35-4.90-42.00-39.25-26.40-14.75-8.90-6.20-3.80-5.90
Diluted Shares Outstanding4.7M4.89M4.95M5.79M7.4M10.82M11.02M15.48M19.02M19.23M
Basic Shares Outstanding4.68M4.89M4.95M5.79M7.4M10.82M11.02M15.48M19.02M19.23M
Dividend Payout Ratio----------

Balance Sheet

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+399.53M300.26M220.81M198.83M204.55M207.37M114.52M223.07M158.91M44.39M
Cash & Short-Term Investments385.79M282.93M194.08M167.81M193.25M196.35M77.3M209.19M141.37M32.46M
Cash Only385.79M282.93M194.08M167.81M193.25M196.35M77.3M209.19M141.37M32.46M
Short-Term Investments0000000000
Accounts Receivable11.53M13.61M19.87M20.15M5.41M7.86M33.07M10.49M15.45M10.39M
Days Sales Outstanding19.05K626.87629.47574.04134.23254.432.11K798358.43-
Inventory2.21M02.89M2.14M2.29M002.68M00
Days Inventory Outstanding5.76K-307.4155.23---48.19--
Other Current Assets12.56M020.79M25.25M0001K00
Total Non-Current Assets+10.01M16.9M29.48M35.92M67.17M64.87M31.81M23.44M24.07M21.27M
Property, Plant & Equipment6.66M13.77M25.07M27.64M48.6M34.9M24.92M17.61M17.93M16.81M
Fixed Asset Turnover0.03x0.58x0.46x0.46x0.30x0.32x0.23x0.27x0.88x-
Goodwill000000066100
Intangible Assets112.14K105.9K173.14K41.01K48K41K22K9.34K58K40K
Long-Term Investments1.65M1.45M1.88M590.48K5.12M4.58M3.97M1.66M3.68M4.31M
Other Non-Current Assets731.31K674.04K1.55M5.78M13.41M25.35M2.9M5.83M2.4M111K
Total Assets+409.53M317.16M250.28M234.76M271.73M272.25M146.32M246.52M182.99M65.66M
Asset Turnover0.00x0.02x0.05x0.05x0.05x0.04x0.04x0.02x0.09x-
Asset Growth %1.07%-0.23%-0.21%-0.06%0.16%0%-0.46%0.68%-0.26%-0.64%
Total Current Liabilities+19.11M31.99M50.58M59.52M54M52.71M31.4M29.52M37.34M31.14M
Accounts Payable11.97M15.14M23.85M39.05M24M20.34M11.43M14.47M23.3M22.03M
Days Payables Outstanding31.22K3.9K2.54K2.83K--449.9260.24-1.18K
Short-Term Debt410.39K813.04K3.89M3.49M4.33M4.43M3.51M1.13M883K846K
Deferred Revenue (Current)943.66K1000K1000K1000K1000K1000K1000K1000K00
Other Current Liabilities5.33M10.33M18.31M2.92M21.63M22.68M12.13M9.82M11.79M7.42M
Current Ratio20.90x9.38x4.37x3.34x3.79x3.93x3.65x7.56x4.26x1.43x
Quick Ratio20.79x9.38x4.31x3.30x3.75x3.93x3.65x7.47x4.26x1.43x
Cash Conversion Cycle-6.42K--1.6K-2.1K---585.95--
Total Non-Current Liabilities+6.18M17.26M16.83M9.46M24.54M14.04M15.9M22.54M5.46M7.13M
Long-Term Debt5.6M4.47M2.57M1.75M810K543K0000
Capital Lease Obligations000022M10.5M7.15M1.13M4.53M6.3M
Deferred Tax Liabilities0000000000
Other Non-Current Liabilities584.57K12.8M14.26M7.71M1.74M3M8.75M21.42M934K838K
Total Liabilities25.3M49.26M67.4M68.98M78.54M66.75M47.29M52.06M42.8M38.27M
Total Debt+6.01M5.28M6.46M5.24M27.14M15.47M10.66M4.15M6.55M7.8M
Net Debt-379.78M-277.65M-187.62M-162.57M-166.12M-180.88M-66.64M-205.04M-134.81M-24.66M
Debt / Equity0.02x0.02x0.04x0.03x0.14x0.08x0.11x0.02x0.05x0.28x
Debt / EBITDA----------
Net Debt / EBITDA----------
Interest Coverage-340.40x-6919.26x-43.60x-396.28x-95.49x-219.40x-142.92x-226.30x--
Total Equity+384.24M267.9M182.88M165.78M193.19M205.49M99.03M194.45M140.19M27.39M
Equity Growth %1.11%-0.3%-0.32%-0.09%0.17%0.06%-0.52%0.96%-0.28%-0.8%
Book Value per Share81.8254.7736.9428.6626.1018.998.9912.567.371.42
Total Shareholders' Equity384.24M267.9M182.88M165.78M193.19M205.49M99.03M194.45M140.19M27.39M
Common Stock2.89M2.72M3.52M4.12M5.64M6.52M6.54M10.72M10.97M11.65M
Retained Earnings-53.3M-126.35M-207.9M-227M-798.99M-958.54M-98.05M-259.58M-238.86M-286.38M
Treasury Stock0-1.31M00-230K-1.17M0-1.11M-1.26M-1.31M
Accumulated OCI-47.22M-56.23M-185.23M-348.47M-643.87M6.64M-15.39M-13.8M-8.13M-12.19M
Minority Interest0000000000

Cash Flow

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-31.93M-65.68M-160.91M-186.74M-148.35M-165.61M-108.24M-55.7M-79.65M-104.47M
Operating CF Margin %-144.57%-8.29%-13.97%-14.57%-10.09%-14.69%-18.96%-11.6%-5.06%-
Operating CF Growth %0.02%-1.06%-1.45%-0.16%0.21%-0.12%0.35%0.49%-0.43%-0.31%
Net Income-53.3M-126.35M-207.9M-227M-172.01M-159.56M-97.81M-96.27M-72.73M-113.92M
Depreciation & Amortization1.28M1.49M4.12M3.87M2.6M10.46M8.38M13.16M-14M-925K
Stock-Based Compensation12.43M37.9M43.33M35.41M17.24M-1.13M3.12M5.03M6.02M4.62M
Deferred Taxes149.12K126.86K323.75K403.22K00184K000
Other Non-Cash Items353.13K163.27K182.99K1.03M381K220K656K66K99K-3K
Working Capital Changes7.16M20.99M-968.44K-445.6K3.45M-15.6M-22.77M22.32M953K5.75M
Change in Receivables162.25K-1.38M4.22K1.68M34K-2.07M2.15M000
Change in Inventory147.93K-2.17M-5M-2.14M-527K2.33M-16.18M000
Change in Payables9.83M4.02M4.69M12.43M-7.65M-5.08M-7.56M3.46M8.42M272K
Cash from Investing+-6.38M-9.16M-11.03M-11.81M-5.66M-2.87M-433K-100K-808K-757K
Capital Expenditures-5.38M-9.05M-10.62M-6.49M-5.57M-2.79M-918K-754K-677K-2.34M
CapEx % of Revenue24.35%1.14%0.92%0.51%0.38%0.25%0.16%0.16%0.04%-
Acquisitions----------
Investments----------
Other Investing0000-30K26K604K-61101.58M
Cash from Financing+287.53M1.84M402.58K178.62M207.58M149.55M274K194.1M6.77M587K
Debt Issued (Net)----------
Equity Issued (Net)----------
Dividends Paid-1.03M000000000
Share Repurchases----------
Other Financing-26.25K83.23K-163.03K-506.34K3.29M-35K-121.08K-20K00
Net Change in Cash----------
Free Cash Flow+-37.31M-74.73M-171.53M-193.23M-153.94M-168.42M-109.16M-56.45M-80.33M-106.81M
FCF Margin %-168.92%-9.43%-14.89%-15.08%-10.47%-14.94%-19.12%-11.76%-5.11%-
FCF Growth %-0.1%-1%-1.3%-0.13%0.2%-0.09%0.35%0.48%-0.42%-0.33%
FCF per Share-7.94-15.28-34.64-33.40-20.80-15.57-9.91-3.65-4.22-5.55
FCF Conversion (FCF/Net Income)0.66x0.52x0.91x0.98x0.86x1.04x1.11x0.58x1.10x0.92x
Interest Paid0000000000
Taxes Paid0000000000

Key Ratios

Metric2015201620172018201920202021202220232024
Return on Equity (ROE)-17.13%-38.75%-78.62%-109.14%-95.84%-80.04%-64.24%-65.63%-43.47%-135.72%
Return on Invested Capital (ROIC)-651.79%---4441.01%-847.19%-461.04%-259.52%-664.89%-1067.09%-2231.7%
Gross Margin36.63%100%100%100%100%100%-62.46%-322.9%100%-
Net Margin-21969.51%-1593.88%-1538.29%-1484.65%-1169.51%-1415%-1713.54%-2006.25%-462.4%-
Debt / Equity0.02x0.02x0.04x0.03x0.14x0.08x0.11x0.02x0.05x0.28x
Interest Coverage-340.40x-6919.26x-43.60x-396.28x-95.49x-219.40x-142.92x-226.30x--
FCF Conversion0.66x0.52x0.91x0.98x0.86x1.04x1.11x0.58x1.10x0.92x
Revenue Growth-13.93%3489.36%45.31%11.25%14.77%-23.33%-49.38%-15.91%227.67%-100%

Frequently Asked Questions

Growth & Financials

DBV Technologies S.A. (DBVT) reported $0.5M in revenue for fiscal year 2024. This represents a 213% increase from $0.2M in 2011.

DBV Technologies S.A. (DBVT) saw revenue decline by 100.0% over the past year.

DBV Technologies S.A. (DBVT) reported a net loss of $125.5M for fiscal year 2024.

Dividend & Returns

DBV Technologies S.A. (DBVT) has a return on equity (ROE) of -135.7%. Negative ROE indicates the company is unprofitable.

DBV Technologies S.A. (DBVT) had negative free cash flow of $98.3M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.